北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 妇科肿瘤中心  > 期刊论文
学科主题: 临床医学
题名:
Advanced primary peritoneal carcinoma: clinicopathological and prognostic factor analyses
作者: Zhang, Chao; Li, Xiao-ping; Cui, Heng; Shen, Dan-hua; Wei, Li-hui
关键词: primary peritoneal carcinoma (PPC) ; cytoreductive surgery ; chemotherapy ; immunohistochemistry ; prognosis
刊名: JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B
发表日期: 2008-06-01
DOI: 10.1631/jzus.B0820051
卷: 9, 期:6, 页:435-440
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Biochemistry & Molecular Biology ; Biotechnology & Applied Microbiology ; Medicine, Research & Experimental
研究领域[WOS]: Biochemistry & Molecular Biology ; Biotechnology & Applied Microbiology ; Research & Experimental Medicine
关键词[WOS]: PAPILLARY SEROUS CARCINOMA ; OVARIAN-CARCINOMA ; STAGE-III ; EXTRAOVARIAN ; ADENOCARCINOMA ; CISPLATIN ; CYCLOPHOSPHAMIDE ; PACLITAXEL ; SURFACE ; CANCER
英文摘要:

Objective: To investigate the factors favoring a positive prognosis for advanced primary peritoneal carcinoma (PPC). Methods: Twenty-four cases meeting the criteria for PPC were analyzed retrospectively for the clinicopathologic profiles. Immunohistochemistry was used to determine the expressions of p53, Top2 alpha, Ki-67 and Her-2/neu. Then all these clinicopathological factors and molecular markers were correlated with the prognosis. Results: There were 15 cases of primary peritoneal serous papillary carcinoma (PPSPC), 6 cases of mixed epithelial carcinoma (MEC) and 3 cases of malignant mixed Mullerian tumor (MMMT). All patients underwent cytoreductive surgery with optimal debulking achieved in 3 cases. Among those receiving first-line chemotherapy, 13 patients received the TP regimen (paclitaxel-cisplatin or carboplatin) and 7 patients received the PAC regimen (cisplatin-doxorubicin-cyclophosphamide). The median overall survival of all patients was 42 months, while the breakdown for survival time for patients with PPSPC, MMT and MEC was 44, 13 and 19 months, respectively. The expressions of p53, Top2 alpha and Ki-67 were all demonstrated in 11 cases respectively. None showed the expression of Her-2/neu. There were significant differences in the median survival between patients with PPSPC and those with MMMT (44 months vs 13 months, P < 0.05), also between patients receiving TP combination and those receiving the PAC regimen (75 months vs 28 months, P < 0.05). Another significant difference in the median progression-free survival (PFS) was identified between patients with positive p53 immunostaining and those with negative p53 immunostaining (15 months vs 47 months, P < 0.05), whereas age, menopausal status, residual tumor size and the other molecular factors did not significantly impact survival. Conclusion: Patients with PPC should be treated with a comprehensive management plan including appropriate cytoreductive surgery and responsive chemotherapy. Overestimating an optimal debulking surgery may not benefit survival. The pathologic subtype, chemotherapy regimen and p53 overexpression were significant prognostic factors.

语种: 英语
WOS记录号: WOS:000256477000001
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/67896
Appears in Collections:北京大学第二临床医学院_妇科肿瘤中心_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: Peking Univ, Peoples Hosp, Gynecol Oncol Ctr, Dept Pathol, Beijing 100044, Peoples R China

Recommended Citation:
Zhang, Chao,Li, Xiao-ping,Cui, Heng,et al. Advanced primary peritoneal carcinoma: clinicopathological and prognostic factor analyses[J]. JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B,2008,9(6):435-440.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Zhang, Chao]'s Articles
[Li, Xiao-ping]'s Articles
[Cui, Heng]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Zhang, Chao]‘s Articles
[Li, Xiao-ping]‘s Articles
[Cui, Heng]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace